Navigation Links
Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
Date:10/26/2007

EMERYVILLE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) (the "Company") today announced that it has priced a public offering of 10,000,000 shares of common stock at a price to the public of $2.50 per share and 5,000,000 warrants to purchase shares of common stock at $3.50 per share at a price of $0.10 per warrant. The Company has granted a 30-day option to the underwriters to purchase up to an additional 15% of the offering to cover over-allotments. The net proceeds to the company of the offering are approximately $24.0 million, after payment of underwriting discounts and commissions, but excluding estimated offering expenses.

BMO Capital Markets Corp. and Canaccord Adams Inc. acted as joint book- running managers for the offering, with Merriman Curhan Ford & Co. (Amex: MEM) acting as a co-manager.

These shares were issued pursuant to an effective shelf registration statement. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus may be obtained from: BMO Capital Markets Corp., Attn: Prospectus Delivery Department, 3 Times Square, New York, New York 10036; Telephone: (212) 702-1969. A prospectus supplement relating to the offering has been filed with the SEC, and is available along with the base prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at http://www.sec.gov/.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol BNVI. For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ATLANTA , March 27, 2017 Cousins Properties ... of the world,s leading biotechnology companies, has signed a 10-year, ... foot Class A office asset located in the Westshore submarket ... "We are thrilled that Amgen has chosen Corporate Center for ... Larry Gellerstedt , president and chief executive officer of ...
(Date:3/27/2017)... Md. , March 27, 2017  The ... billion for 2016, according to a new report ... medical lab testing is performed to evaluate disease ... individual therapy, among other reasons.  The healthcare market ... Market , provides an overview of the ...
(Date:3/27/2017)... ... 27, 2017 , ... PMG Research is pleased to announce its ... The Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses on ... outcomes and bring them closer to the patient. Clinical Trial Collaborations also will present ...
(Date:3/27/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is now offering a ... consumers who want to have their DarioHealth products reimbursed ... alliance agreements with partners across the U.S. who will ... approved, will supply and bill the customer,s insurance for ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
Breaking Biology News(10 mins):